Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera

Sug Kyun Shin, Sung Kyu Ha, Kang Wook Lee, Tae Hyun Yoo, Sung Ro Yun, Se Hee Yoon, Sung Jo Kim, Soo Kyeong Lee, Tae Hwe Heo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although erythropoietin (EPO)-related pure red-cell aplasia (PRCA) is a rare disorder, attention still needs to be paid because underline mechanism of EPO immunogenicity is various and controversial. Among several assay systems for screening of anti-EPO binding antibodies (Abs), we adopted and setup the bridging ELISA using streptavidin-coated plate. To test their neutralizing activities, cell-based neutralizing (NT) bioassay was setup. When we analyzed serum samples by using these two assays, we found two positive results in the two samples. In the sample 1, 411.9. ng/ml of anti-EPO Abs were found and neutralizing activity of 36.2% at 1:5 serum dilution was detected. In the sample 2, 40.5. ng/ml of anti-EPO Abs were found and neutralizing activity of 96.7% was detected. Our results indicate that the higher anti-EPO antibody (Ab) level in a serum does not always lead to the stronger neutralizing activity. This report gives crucial consideration to the needs of establishing clear criteria to link various assay parameters with the onset of PRCA and its progression.

Original languageEnglish
Pages (from-to)289-293
Number of pages5
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume52
Issue number2
DOIs
Publication statusPublished - 2010 Jun 1

Fingerprint

Bioassay
Erythropoietin
Neutralizing Antibodies
Biological Assay
Enzyme-Linked Immunosorbent Assay
Antibodies
Serum
Pure Red-Cell Aplasia
Anti-Idiotypic Antibodies
Assays
Streptavidin
Dilution
Screening

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this

Shin, Sug Kyun ; Ha, Sung Kyu ; Lee, Kang Wook ; Yoo, Tae Hyun ; Yun, Sung Ro ; Yoon, Se Hee ; Kim, Sung Jo ; Lee, Soo Kyeong ; Heo, Tae Hwe. / Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera. In: Journal of Pharmaceutical and Biomedical Analysis. 2010 ; Vol. 52, No. 2. pp. 289-293.
@article{72aae7b4775b4d9e8d2b2ec29f9f016a,
title = "Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera",
abstract = "Although erythropoietin (EPO)-related pure red-cell aplasia (PRCA) is a rare disorder, attention still needs to be paid because underline mechanism of EPO immunogenicity is various and controversial. Among several assay systems for screening of anti-EPO binding antibodies (Abs), we adopted and setup the bridging ELISA using streptavidin-coated plate. To test their neutralizing activities, cell-based neutralizing (NT) bioassay was setup. When we analyzed serum samples by using these two assays, we found two positive results in the two samples. In the sample 1, 411.9. ng/ml of anti-EPO Abs were found and neutralizing activity of 36.2{\%} at 1:5 serum dilution was detected. In the sample 2, 40.5. ng/ml of anti-EPO Abs were found and neutralizing activity of 96.7{\%} was detected. Our results indicate that the higher anti-EPO antibody (Ab) level in a serum does not always lead to the stronger neutralizing activity. This report gives crucial consideration to the needs of establishing clear criteria to link various assay parameters with the onset of PRCA and its progression.",
author = "Shin, {Sug Kyun} and Ha, {Sung Kyu} and Lee, {Kang Wook} and Yoo, {Tae Hyun} and Yun, {Sung Ro} and Yoon, {Se Hee} and Kim, {Sung Jo} and Lee, {Soo Kyeong} and Heo, {Tae Hwe}",
year = "2010",
month = "6",
day = "1",
doi = "10.1016/j.jpba.2010.01.022",
language = "English",
volume = "52",
pages = "289--293",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",
number = "2",

}

Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera. / Shin, Sug Kyun; Ha, Sung Kyu; Lee, Kang Wook; Yoo, Tae Hyun; Yun, Sung Ro; Yoon, Se Hee; Kim, Sung Jo; Lee, Soo Kyeong; Heo, Tae Hwe.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 52, No. 2, 01.06.2010, p. 289-293.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera

AU - Shin, Sug Kyun

AU - Ha, Sung Kyu

AU - Lee, Kang Wook

AU - Yoo, Tae Hyun

AU - Yun, Sung Ro

AU - Yoon, Se Hee

AU - Kim, Sung Jo

AU - Lee, Soo Kyeong

AU - Heo, Tae Hwe

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Although erythropoietin (EPO)-related pure red-cell aplasia (PRCA) is a rare disorder, attention still needs to be paid because underline mechanism of EPO immunogenicity is various and controversial. Among several assay systems for screening of anti-EPO binding antibodies (Abs), we adopted and setup the bridging ELISA using streptavidin-coated plate. To test their neutralizing activities, cell-based neutralizing (NT) bioassay was setup. When we analyzed serum samples by using these two assays, we found two positive results in the two samples. In the sample 1, 411.9. ng/ml of anti-EPO Abs were found and neutralizing activity of 36.2% at 1:5 serum dilution was detected. In the sample 2, 40.5. ng/ml of anti-EPO Abs were found and neutralizing activity of 96.7% was detected. Our results indicate that the higher anti-EPO antibody (Ab) level in a serum does not always lead to the stronger neutralizing activity. This report gives crucial consideration to the needs of establishing clear criteria to link various assay parameters with the onset of PRCA and its progression.

AB - Although erythropoietin (EPO)-related pure red-cell aplasia (PRCA) is a rare disorder, attention still needs to be paid because underline mechanism of EPO immunogenicity is various and controversial. Among several assay systems for screening of anti-EPO binding antibodies (Abs), we adopted and setup the bridging ELISA using streptavidin-coated plate. To test their neutralizing activities, cell-based neutralizing (NT) bioassay was setup. When we analyzed serum samples by using these two assays, we found two positive results in the two samples. In the sample 1, 411.9. ng/ml of anti-EPO Abs were found and neutralizing activity of 36.2% at 1:5 serum dilution was detected. In the sample 2, 40.5. ng/ml of anti-EPO Abs were found and neutralizing activity of 96.7% was detected. Our results indicate that the higher anti-EPO antibody (Ab) level in a serum does not always lead to the stronger neutralizing activity. This report gives crucial consideration to the needs of establishing clear criteria to link various assay parameters with the onset of PRCA and its progression.

UR - http://www.scopus.com/inward/record.url?scp=77349115439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77349115439&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2010.01.022

DO - 10.1016/j.jpba.2010.01.022

M3 - Article

C2 - 20133098

AN - SCOPUS:77349115439

VL - 52

SP - 289

EP - 293

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

IS - 2

ER -